Aditxt Inc

ADTX

Company Profile

  • Business description

    Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures and blocking of unwanted immune responses in autoimmune diseases. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) ADI-100, which utilizes a novel approach that mimics, the way bodies naturally induce tolerance to tissues. The company operates in one segment, which is focused on the discovery and development of biopharmaceutical products.

  • Contact

    2569 Wyandotte Street
    Suite 101
    Mountain ViewCA94043
    USA

    T: +1 650 870-1200

    https://www.aditxt.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    26

Stocks News & Analysis

stocks

ASX tech share tracking below guidance

Moat Rating downgraded for overvalued shares.
stocks

After plunge ASX blue chip undervalued

This company earns a moat from our analysts.
stocks

Older cohorts the budget losers, not necessarily the ASX listed insurers

Proposed legislation removes health insurance rebates.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,717.0082.40-0.94%
CAC 408,117.42135.661.70%
DAX 4024,737.24336.591.38%
Dow JONES (US)50,009.35645.471.31%
FTSE 10010,432.34101.790.99%
HKSE25,651.12146.73-0.57%
NASDAQ26,270.36399.651.54%
Nikkei 22559,804.41746.18-1.23%
NZX 50 Index12,816.9655.930.44%
S&P 5007,432.9779.361.08%
S&P/ASX 2008,496.6076.50-0.89%
SSE Composite Index4,162.187.35-0.18%

Market Movers